Table 3.
Characteristics of studies included in meta-analysis.
| Study | Demographic characteristics | p.G60= mutational status | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ethnicity | Age (mean± SD/range) |
Etiology of CP |
Cohort | Allele frequency | Genotype distribution | Genotyping method | ||||
| Major (C) | Minor (T) | Wild type (CC) |
Heterozygous (CT) |
Homozygous (TT) |
||||||
| Masson et al., 2008 | French | NA/≤20 (ICP); NA (FCP, HCP) | ICP FCP HCP |
CP | 483/574 (84.1%) |
91/574 (15.9%) |
209/287 (72.8%) |
65/287 (22.7%) |
13/287 (4.5%) |
Direct sequencing/Sanger |
| Controls | 617/700 (88.1%) |
83/700 (11.9%) |
277/350 (79.1%) |
63/350 (18%) |
10/350 (2.9%) |
Direct sequencing/Sanger or DHPLC | ||||
| Paliwal et al., 2013 | Indian | NA/NA | TCP ICP |
CP | 954/1168 (81.7%) |
214/1168 (18.3%) |
393/584 (67.3%) |
168/584 (28.8%) |
23/584 (3.9%) |
Direct sequencing/Sanger |
| Controls | 1102/1196 (92.1%) |
94/1196 (7.9%) |
507/598 (84.8%) |
88/598 (14.7%) |
3/598 (0.5%) |
Direct sequencing/Sanger | ||||
| Larusch et al., 2015 | North American (European ancestry) | 50.5±16.1/NA | ACP NACP | CP | 1138/1368 (83.2%) |
230/1368 (16.8%) |
484/684 (70.8%) |
170/684 (24.8%) |
30/684 (4.4%) |
Taqman SNP genotyping assay and/or direct sequencing/Sanger |
| Controls | 1807/2026 (89.2%) |
219/2026 (10.8%) |
804/1013 (79.4%) |
199/1013 (19.6%) |
10/1013 (1%) |
Taqman SNP genotyping assay and/or direct sequencing/Sanger | ||||
| Rosendahl et al., 2018 | European | 43±17.1/1-98 | ACP NACP | CP | 3895/4672 (83.4%) |
777/4672 (16.6%) |
1627/2336 (69.7%) |
641/2336 (27.4%) |
68/2336 (2.9%) |
Illumina BeadChip arrays |
| Controls | 10415/11536 (90.3%) |
1121/11536 (9.7%) |
4715/5768 (81.7%) |
985/5768 (17.1%) |
68/5768 (1.2%) |
Illumina BeadChip arrays | ||||
| Grabarczyk et al., 2017 | Polish | NA/1.5-17.5 | NA | CP | 185/272 (68%) |
87/272 (32%) |
69/136 (50.7%) |
47/136 (34.6%) |
20/136 (14.7%) |
Direct sequencing/Sanger |
| Controls | 718/802 (89.5%) |
84/802 (10.5%) |
321/401 (80%) |
76/401 (19%) |
4/401 (1%) |
HRM-PCR | ||||
| Zou et al., 2018 | Chinese | 40.7±16/6-85 | ICP ACP SCP |
CP | 2104/2122 (99.2%) |
18/2122 (0.8%) |
1043/1061 (98.3%) |
18/1061 (1.7%) |
0/1061 (0%) |
Targeted next-generation sequencing |
| Controls | 2389/2392 (99.9%) |
3/2392 (0.1%) |
1193/1196 (99.7%) |
3/1196 (0.3%) |
0/1196 (0%) |
Targeted next-generation sequencing | ||||
| Hungarian CP cohort | Hungarian | 55.7±11.7/21-85 | ACP NACP |
CP | 473/582 (81.3%) |
109/582 (18.7%) |
193/291 (66.3%) |
87/291 (29.9%) |
11/291 (3.8%) |
Direct sequencing/Sanger |
| Controls | 627/698 (89.8%) |
71/698 (10.2%) |
279/349 (79.9%) |
69/349 (19.8%) |
1/349 (0.3%) |
Direct sequencing/Sanger | ||||
CP, chronic pancreatitis; ACP, alcoholic chronic pancreatitis; NACP, non-alcoholic chronic pancreatitis; ICP, idiopathic chronic pancreatitis; FCP, familial chronic pancreatitis; HCP, hereditary chronic pancreatitis; TCP, tropical chronic pancreatitis; SCP, smoking-associated chronic pancreatitis; DHPLC, denaturing high performance liquid chromatography; HRM-PCR, high resolution melting polymerase chain reaction; NA, not available